Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 3Withdrawn 2Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Myelodysplastic Syndromes 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma, Follicular 2Leukemia, Myelomonocytic, Chronic 2Leukemia, Myeloid, Acute 2Breast Neoplasms 2Anemia, Refractory, with Excess of Blasts 2Uveal Melanoma 1Recurrence 1Oligodendroglioma 1Neoplasm Metastasis 1Multiple Myeloma 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Lymphoma, Extranodal NK-T-Cell 1Lymphoma, B-Cell 1Lymphoma 1Lung Neoplasms 1Leukemia, Myelomonocytic, Juvenile 1Leukemia, Myeloid, Chronic-Phase 1Leukemia, Myeloid, Accelerated Phase 1Leukemia, Megakaryoblastic, Acute 1Leukemia, Erythroblastic, Acute 1Leukemia, Biphenotypic, Acute 1Leukemia 1Hematologic Diseases 1Graft vs Host Disease 1Gliosarcoma 1Glioma 1

Interventions

Rituximab 16Cyclophosphamide 16Prednisone 7Doxorubicin 7pirtobrutinib 6fludarabine 6Vincristine 6Lenalidomide 6venetoclax 5pembrolizumab 5fludarabine phosphate 5Etoposide 5Bendamustine Hydrochloride 5ibrutinib 4acalabrutinib 4Specimen Handling 4Magnetic Resonance Spectroscopy 4Dexamethasone 4CT-P10 4polatuzumab vedotin 3etoposide phosphate 3Immunotherapy, Adoptive 3tazemetostat 2liposomal doxorubicin 2Nivolumab 2Injections 2Ifosfamide 2Gemcitabine 2Cisplatin 2Carboplatin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Lymphoma, B-Cell × Vorinostat × Clear all
NCT03150329 2025-09-03

Pembrolizumab and Vorinostat in Patients With Relapsed or Refractory DLBCL, FCL or HL.

City of Hope Medical Center

Phase 1 Active not recruiting
52 enrolled 13 charts
Lymphoid

Lymphoma, Follicular, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡